microdosing glp-1 receptor agonists GLP-1s: How (and Why) It Works Microdosing GLP-1s: Reduce Inflammation, Support

Species: Dog Species: Cat

doi: 10.1111/jnc.14037, 18 GuilleminC.CharonitisM.BeliyN.RequierF.DelrueG.LommersE.et al

Certain factorsincluding skin thickness, blood flow, and blood vessel elasticitydetermine whether a bruise appears after each injection

10.1038/s42255-024-01149-x 176 ZhangY

It makes it an exceptional choice for enhancing the skin's barrier, providing wrinkle care, and brightening the complexion

The STEP trials evaluated semaglutide and showed average weight reductions of around 15% over 68 weeks, while SURMOUNT trialsfocusing on tirzepatide, a dual GIP/GLP-1 receptor agonistdemonstrated even greater reductions, with participants losing up to 21% of their body weight over 72 weeks (Note: GIP = Glucose-dependent insulinotropic polypeptide)